Quadrant Capital Group LLC Intercept Pharmaceuticals, Inc. Transaction History

Quadrant Capital Group LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$12.21 - $19.7 $781 - $1,260	64 New	64 $1,000
Q1 2022 May 06, 2022	SELL	$13.37 - $17.79 $7,634 - $10,158	-571 Closed	0 $0
Q4 2021 Feb 01, 2022	SELL	$14.28 - $19.53 $114 - $156	-8 Reduced 1.38%	571 $9,000
Q3 2021 Nov 12, 2021	BUY	$12.99 - $20.47 $7,521 - $11,852	579 New	579 $9,000
Q2 2021 Aug 09, 2021	SELL	$15.46 - $24.5 $139 - $220	-9 Closed	0 $0

Q1 2021 May 12, 2021	SELL	$19.33 - $37.75 $115 - $226	-6 Reduced 40.0%	9 $0
Q4 2020 Feb 16, 2021	BUY	$24.48 - $42.47 $367 - $637	15 New	15 $0
Q3 2019 Oct 24, 2019	SELL	$58.69 - $80.46 $16,374 - $22,448	-279 Closed	0 $0
Q2 2019 Jul 24, 2019	BUY	$77.77 - $120.68 $21,697 - $33,669	279 New	279 $22,000

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

Stay updated on Quadrant Capital Group LLC with notifications on news.